Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches

References

• Wiersinga WJ, De Vos AF, de Beer R, et al. Inflammation patterns induced by different Burkholderia species in mice. Cell Microbiol. 2008;10(1):81–87.
   PubMed Web of Science ®Google Scholar
• Coenye T, Vandamme P. Diversity and significance of Burkholderia species occupying diverse ecological niches. Environ Microbiol. 2003;5(9):719–729.
   PubMed Web of Science ®Google Scholar
• Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18(2):383–416.
   PubMed Web of Science ®Google Scholar
• Silva EB, Dow SW. Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol. 2013;3:10.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035–1044.
   PubMed Web of Science ®Google Scholar
• Allwood EM, Devenish RJ, Prescott M, et al. Strategies for intracellular survival of Burkholderia pseudomallei. Front Microbiol. 2011;2:170.
   PubMed Web of Science ®Google Scholar
• Arjcharoen S, Wikraiphat C, Pudla M, et al. Fate of a Burkholderia pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line RAW 264.7: possible role for the O-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival. Infect Immun. 2007;75(9):4298–4304.
   PubMed Web of Science ®Google Scholar
• Utaisincharoen P, Anuntagool N, Limposuwan K, et al. Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages. Infect Immun. 2003;71(6):3053–3057.
   PubMed Web of Science ®Google Scholar
• Baral P, Utaisincharoen P. Involvement of signal regulatory protein alpha, a negative regulator of Toll-like receptor signaling, in impairing the MyD88-independent pathway and intracellular killing of Burkholderia pseudomallei-infected mouse macrophages. Infect Immun. 2012;80(12):4223–4231.
   PubMed Web of Science ®Google Scholar
• Gilling DH, Luna VA, Pflugradt C. The identification and differentiation between Burkholderia mallei and Burkholderia pseudomallei using one gene pyrosequencing. Int Scholarly Res Notices. 2014;2014:1–10.
   Google Scholar
• Brett PJ, Burtnick MN, Su H, et al. iNOS activity is critical for the clearance of Burkholderia mallei from infected RAW 264.7 murine macrophages. Cell Microbiol. 2008;10(2):487–498.
   PubMed Web of Science ®Google Scholar
• Lu R, Popov V, Patel J, et al. Burkholderia mallei and Burkholderia pseudomallei stimulate differential inflammatory responses from human alveolar type II cells (ATII) and macrophages. Front Cell Infect Microbiol. 2012;2:165.
   PubMed Web of Science ®Google Scholar
• Dvorak GD, Spickler AR. Glanders. J Am Vet Med Assoc. 2008;233(4):570–577.
   PubMed Web of Science ®Google Scholar
• Khan I, Wieler LH, Melzer F, et al. Glanders in animals: a review on epidemiology, clinical presentation, diagnosis and countermeasures. Transbound Emerg Dis. 2013;60(3):204–221.
   PubMed Web of Science ®Google Scholar
• Mota RA, Da Fonseca Oliveira AA, da Silva AM, et al. Glanders in donkeys (Equus Asinus) in the state of pernambuco, Brazil: A case report. Brazilian J Microbiol: [publication of the Brazilian Society for Microbiology]. 2010;41(1):146–149.
   PubMed Web of Science ®Google Scholar
• Elschner MC, Klaus CU, Liebler-Tenorio E, et al. Burkholderia mallei infection in a horse imported from Brazil. Equine Vet Educ. 2009;21(3):147–150.
   Web of Science ®Google Scholar
• OIE Glanders, Germany. http://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?reportid=17092OIE world Organisation for Animal Health. OIE, Jan 30, 2015. Web. Jan 14, 2016.
   Google Scholar
• Memisevic V, Zavaljevski N, Pieper R, et al. Novel Burkholderia mallei virulence factors linked to specific host-pathogen protein interactions. Mol Cell Proteomics: MCP. 2013;12(11):3036–3051.
   PubMed Web of Science ®Google Scholar
• Memisevic V, Zavaljevski N, Rajagopala SV, et al. Mining host-pathogen protein interactions to characterize Burkholderia mallei infectivity mechanisms. PLoS Comput Biol. 2015;11(3):e1004088.
   PubMed Web of Science ®Google Scholar
• Chin CY, Monack DM, Nathan S. Genome wide transcriptome profiling of a murine acute melioidosis model reveals new insights into how Burkholderia pseudomallei overcomes host innate immunity. BMC Genomics. 2010;11:672.
   PubMed Web of Science ®Google Scholar
• Koh GC, Schreiber MF, Bautista R, et al. Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling. Plos One. 2013;8(1):e54961.
   PubMed Web of Science ®Google Scholar
• Baral P, Utaisincharoen P. Sterile-alpha- and armadillo motif-containing protein inhibits the TRIF-dependent downregulation of signal regulatory protein alpha to interfere with intracellular bacterial elimination in Burkholderia pseudomallei-infected mouse macrophages. Infect Immun. 2013;81(9):3463–3471.
   PubMed Web of Science ®Google Scholar
• Pudla M, Limposuwan K, Utaisincharoen P. Burkholderia pseudomallei-induced expression of a negative regulator, sterile-alpha and Armadillo motif-containing protein, in mouse macrophages: a possible mechanism for suppression of the MyD88-independent pathway. Infect Immun. 2011;79(7):2921–2927.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, van’t Veer C, van den Pangaart PS, et al. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med. 2009;37(2):569–576.
   PubMed Web of Science ®Google Scholar
• Ekchariyawat P, Pudla S, Limposuwan K, et al. Expression of suppressor of cytokine signaling 3 (SOCS3) and cytokine-inducible Src homology 2-containing protein (CIS) induced in Burkholderia pseudomallei–infected mouse macrophages requires bacterial internalization. Microb Pathog. 2007;42(2–3):104–110.
   PubMed Web of Science ®Google Scholar
• Ekchariyawat P, Pudla S, Limposuwan K, et al. Burkholderia pseudomallei-induced expression of suppressor of cytokine signaling 3 and cytokine-inducible src homology 2-containing protein in mouse macrophages: a possible mechanism for suppression of the response to gamma interferon stimulation. Infect Immun. 2005;73(11):7332–7339.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Dessing MC, Kager PA, et al. High-throughput mRNA profiling characterizes the expression of inflammatory molecules in sepsis caused by Burkholderia pseudomallei. Infect Immun. 2007;75(6):3074–3079.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Dessing MC, van der Poll T. Gene-expression profiles in murine melioidosis. Microbes and Infection/Institut Pasteur. 2008;10(8):868–877.
   PubMed Web of Science ®Google Scholar
• Asakrah S, Nieves W, Mahdi Z, et al. Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei. PLoS Negl Trop Dis. 2013;7(5):e2212.
   PubMed Web of Science ®Google Scholar
• Tan KS, Chen Y, Lim YC, et al. Suppression of host innate immune response by Burkholderia pseudomallei through the virulence factor TssM. J Immunology. 2010;184(9):5160–5171.
   PubMed Web of Science ®Google Scholar
• Utaisincharoen P, Tangthawornchaikul N, Kespichayawattana W, et al. Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol Immunol. 2001;45(4):307–313.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Suzuki M, Sakaguchi R, et al. SOCS, Inflammation, and Autoimmunity. Front Immunol. 2012;3:20.
   PubMed Web of Science ®Google Scholar
• Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol. 2006;177(11):7497–7504.
   PubMed Web of Science ®Google Scholar
• Woodward EA, Prêle CM, Nicholson SE, et al. The anti-inflammatory effects of interleukin-4 are not mediated by suppressor of cytokine signalling-1 (SOCS1). Immunology. 2010;131(1):118–127.
   PubMed Web of Science ®Google Scholar
• Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27–55.
   PubMed Web of Science ®Google Scholar
• Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5(6):446–458.
   PubMed Web of Science ®Google Scholar
• Kondo T, Kawai T, Akira S. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol. 2012;33(9):449–458.
   PubMed Web of Science ®Google Scholar
• Zakharova M, Ziegler HK. Paradoxical anti-inflammatory actions of TNF-: Inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J Immunol. 2005;175(8):5024–5033.
   PubMed Web of Science ®Google Scholar
• Massey S, Yeager LA, Blumentritt CA, et al. Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection. Sci Rep. 2014;4:4305.
   PubMed Web of Science ®Google Scholar
• Tangsudjai S, Pudla M, Limposuwan K, et al. Involvement of the MyD88-independent pathway in controlling the intracellular fate of Burkholderia pseudomallei infection in the mouse macrophage cell line RAW 264.7. Microbiol Immunol. 2010;54(5):282–290.
   PubMed Web of Science ®Google Scholar
• Novem V, Shui G, Wang D, et al. Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clin Vaccine Immunol: CVI. 2009;16(10):1420–1428.
   PubMed Web of Science ®Google Scholar
• Korneev KV, Arbatsky NP, Molinaro A, et al. Structural relationship of the lipid a acyl groups to activation of murine toll-like receptor 4 by lipopolysaccharides from pathogenic strains of Burkholderia mallei, Acinetobacter baumannii, and Pseudomonas Aeruginosa. Fron Immunol. 2015;6:595.
   PubMedGoogle Scholar
• Matsuura M, Kawahara K, Ezaki T, et al. Biological activities of lipopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. FEMS Microbiol Lett. 1996;137(1):79–83.
   PubMed Web of Science ®Google Scholar
• Utaisincharoen P, Tangthawornchaikul N, Kespichayawattana W, et al. Kinetic studies of the production of nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) in macrophages stimulated with Burkholderia pseudomallei endotoxin. Clin Exp Immunol. 2000;122(3):324–329.
   PubMed Web of Science ®Google Scholar
• Chantratita N, Tandhavanant S, Myers ND, et al. Survey of innate immune responses to Burkholderia pseudomallei in human blood identifies a central role for lipopolysaccharide. Plos One. 2013;8(11):e81617.
   PubMed Web of Science ®Google Scholar
• Weehuizen TA, Prior JL, van der Vaart TW, et al. Differential toll-like receptor-signalling of Burkholderia pseudomallei lipopolysaccharide in murine and human models. Plos One. 2015;10(12):e0145397.
   PubMed Web of Science ®Google Scholar
• Wikraiphat C, Charoensap J, Utaisincharoen P, et al. Comparative in vivo and in vitro analyses of putative virulence factors of Burkholderia pseudomallei using lipopolysaccharide, capsule and flagellin mutants. FEMS Immunol Med Microbiol. 2009;56(3):253–259.
   PubMedGoogle Scholar
• Wikraiphat C, Saiprom N, Tandhavanant S, et al. Colony morphology variation of Burkholderia pseudomallei is associated with antigenic variation and O-polysaccharide modification. Infect Immun. 2015;83(5):2127–2138.
   PubMed Web of Science ®Google Scholar
• Wongratanacheewin S, Kespichayawattana W, Intachote P, et al. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004;72(8):4494–4502.
   PubMed Web of Science ®Google Scholar
• Tan ZY, Khah AKL, Sim SH, et al. Synthetic TLR4 agonist as a potential immunotherapy for melioidosis. Open J Immunol. 2013;03(01):1–9.
   Google Scholar
• Judy BM, Taylor K, Deeraksa A, et al. Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. Plos One. 2012;7(3):e34176.
   PubMed Web of Science ®Google Scholar
• Mott TM, Johnston RK, Vijayakumar S, et al. Monitoring therapeutic treatments against infections using imaging techniques. Pathogens. 2013;2:2.
   Google Scholar
• Waag DM, McCluskie MJ, Zhang N, et al. oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun. 2006;74(3):1944–1948.
   PubMed Web of Science ®Google Scholar
• Utaisincharoen P, Anuntagool N, Chaisuriya P, et al. CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). Clin Exp Immunol. 2002;128(3):467–473.
   PubMed Web of Science ®Google Scholar
• Propst KL, Troyer RM, Kellihan LM, et al. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother. 2010;54(5):1785–1792.
   PubMed Web of Science ®Google Scholar
• Goodyear A, Kellihan L, Bielefeldt-Ohmann H, et al. Protection from pneumonic infection with burkholderia species by inhalational immunotherapy. Infect Immun. 2009;77(4):1579–1588.
   PubMed Web of Science ®Google Scholar
• Easton A, Haque A, Chu K, et al. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis. 2011;204(4):636–644.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Anderson R, Huang YY, et al. Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice. Clin Vaccine Immunol: CVI. 2012;19(5):675–683.
   PubMed Web of Science ®Google Scholar
• Breitbach K, Kohler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans R Soc Trop Med Hyg. 2008;102(Suppl 1):S89–94.
   PubMedGoogle Scholar
• Whitlock GC, Deeraksa A, Qazi O, et al. Protective response to subunit vaccination against intranasal and challenge. Procedia Vaccinol. 2010;2(1):2–9.
   PubMedGoogle Scholar
• Scott AE, Laws TR, D’Elia RV, et al. Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule. Clin Vaccine Immunol: CVI. 2013;20(7):1041–1047.
   PubMed Web of Science ®Google Scholar
• Haque A, Chu K, Easton A, et al. A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis. 2006;194(9):1241–1248.
   PubMed Web of Science ®Google Scholar
• Atkins T, Prior RG, Mack K, et al. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun. 2002;70(9):5290–5294.
   PubMed Web of Science ®Google Scholar
• Silva EB, Goodyear A, Sutherland MD, et al. Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine. Infect Immun. 2013;81(12):4626–4634.
   PubMed Web of Science ®Google Scholar
• Cuccui J, Easton A, Chu KK, et al. Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect Immun. 2007;75(3):1186–1195.
   PubMed Web of Science ®Google Scholar
• Norris MH, Propst KL, Kang Y, et al. The Burkholderia pseudomallei Deltaasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infect Immun. 2011;79(10):4010–4018.
   PubMed Web of Science ®Google Scholar
• Muller CM, Conejero L, Spink N, et al. Role of RelA and SpoT in Burkholderia pseudomallei virulence and immunity. Infect Immun. 2012;80(9):3247–3255.
   PubMed Web of Science ®Google Scholar
• Cuccui J, Milne TS, Harmer N, et al. Characterization of the Burkholderia pseudomallei K96243 capsular polysaccharide I coding region. Infect Immun. 2012;80(3):1209–1221.
   PubMed Web of Science ®Google Scholar
• Stevens MP, Haque A, Atkins T, et al. Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology. 2004;150(Pt 8):2669–2676.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Anderson R, Huang YY, et al. Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge. Vaccine. 2014;32(45):5983–5988.
   PubMed Web of Science ®Google Scholar
• Barnes JL, Ketheesan N. Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol Cell Biol. 2007;85(7):551–557.
   PubMed Web of Science ®Google Scholar
• Henderson A, Propst K, Kedl R, et al. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine. 2011;29(32):5304–5312.
   PubMed Web of Science ®Google Scholar
• Sarkar-Tyson M, Smither SJ, Harding SV, et al. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine. 2009;27(33):4447–4451.
   PubMed Web of Science ®Google Scholar
• Healey GD, Elvin SJ, Morton M, et al. Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect Immun. 2005;73(9):5945–5951.
   PubMed Web of Science ®Google Scholar
• Elvin SJ, Healey GD, Westwood A, et al. Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun. 2006;74(3):1706–1711.
   PubMed Web of Science ®Google Scholar
• Ngugi SA, Ventura VV, Qazi O, et al. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine. 2010;28(47):7551–7555.
   PubMed Web of Science ®Google Scholar
• Nelson M, Prior JL, Lever MS, et al. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol. 2004;53(Pt 12):1177–1182.
   PubMed Web of Science ®Google Scholar
• Scott AE, Ngugi SA, Laws TR, et al. Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate. Journal Immunol Res. 2014;2014:392170.
   PubMed Web of Science ®Google Scholar
• Harland DN, Chu K, Haque A, et al. Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect Immun. 2007;75(8):4173–4180.
   PubMed Web of Science ®Google Scholar
• Burtnick MN, Brett PJ, Harding SV, et al. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun. 2011;79(4):1512–1525.
   PubMed Web of Science ®Google Scholar
• Su YC, Wan KL, Mohamed R, et al. Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice. Vaccine. 2010;28(31):5005–5011.
   PubMed Web of Science ®Google Scholar
• Chin CY, Tan SC, Nathan S. Immunogenic recombinant Burkholderia pseudomallei MprA serine protease elicits protective immunity in mice. Front Cell Infect Microbiol. 2012;2:85.
   PubMed Web of Science ®Google Scholar
• Chen YS, Hsiao YS, Lin HH, et al. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine. 2006;24(6):750–758.
   PubMed Web of Science ®Google Scholar
• Druar C, Yu F, Barnes JL, et al. Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol Med Microbiol. 2008;52(1):78–87.
   PubMedGoogle Scholar
• Scott AE, Burtnick MN, Stokes MG, et al. Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis. Infect Immun. 2014;82(8):3206–3213.
   PubMed Web of Science ®Google Scholar
• Garcia-Quintanilla F, Iwashkiw JA, Price NL, et al. Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery. Front Microbiol. 2014;5:381.
   PubMed Web of Science ®Google Scholar
• Nieves W, Asakrah S, Qazi O, et al. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine. 2011;29(46):8381–8389.
   PubMed Web of Science ®Google Scholar
• Nieves W, Petersen H, Judy BM, et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol: CVI. 2014;21(5):747–754.
   PubMed Web of Science ®Google Scholar
• Chen YS, Hsiao YS, Lin HH, et al. CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun. 2006;74(3):1699–1705.
   PubMed Web of Science ®Google Scholar
• Ulrich RL, Amemiya K, Waag DM, et al. Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Vaccine. 2005;23(16):1986–1992.
   PubMed Web of Science ®Google Scholar
• Ulrich RL, Deshazer D, Hines HB, et al. Quorum sensing: a transcriptional regulatory system involved in the pathogenicity of Burkholderia mallei. Infect Immun. 2004;72(11):6589–6596.
   PubMed Web of Science ®Google Scholar
• Bandara AB, DeShazer D, Inzana TJ, et al. A disruption of ctpA encoding carboxy-terminal protease attenuates Burkholderia mallei and induces partial protection in CD1 mice. Microb Pathog. 2008;45(3):207–216.
   PubMed Web of Science ®Google Scholar
• Whitlock GC, Lukaszewski RA, Judy BM, et al. Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei. BMC Immunol. 2008;9:55.
   PubMed Web of Science ®Google Scholar
• Amemiya K. Nonviable Burkholderia mallei induces a mixed Th1- and Th2-Like cytokine response in BALB/c mice. Infect Immun. 2002;70(5):2319–2325.
   PubMed Web of Science ®Google Scholar
• Amemiya K, Meyers JL, Trevino SR, et al. Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice. Vaccine. 2006;24(9):1413–1420.
   PubMed Web of Science ®Google Scholar
• Fernandes PJ, Guo Q, Waag DM, et al. The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model. Infect Immun. 2007;75(6):3027–3032.
   PubMed Web of Science ®Google Scholar
• Torres AG, Gregory AE, Hatcher CL, et al. Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine. 2015;33(5):686–692.
   PubMed Web of Science ®Google Scholar
• Gregory AE, Judy BM, Qazi O, et al. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine. 2015;11(2):447–456.
   PubMed Web of Science ®Google Scholar
• Moustafa DA, Scarff JM, Garcia PP, et al. Recombinant salmonella expressing Burkholderia mallei LPS O antigen provides protection in a murine model of melioidosis and glanders. Plos One. 2015;10(7):e0132032.
   PubMed Web of Science ®Google Scholar
• Mott TM, Vijayakumar S, Sbrana E, et al. Characterization of the Burkholderia mallei tonB mutant and its potential as a backbone strain for vaccine development. PLoS Negl Trop Dis. 2015;9(6):e0003863.
   Web of Science ®Google Scholar
• Graham BS. New approaches to vaccine adjuvants: inhibiting the inhibitor. PLoS Med. 2006;3(1):e57.
   PubMed Web of Science ®Google Scholar
• Song XT, Evel-Kabler K, Rollins L, et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 2006;3(1):e11.
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Funnell SG, Torres AG, et al. Consensus on the development of vaccines against naturally acquired melioidosis. Emerg Infect Dis. 2015;21(6):e1–e7.
   Google Scholar
• Sarkar-Tyson M, Titball RW. Progress toward development of vaccines against melioidosis: A review. Clin Ther. 2010;32(8):1437–1445.
   PubMed Web of Science ®Google Scholar
• Choh LC, Ong GH, Vellasamy KM, et al. Burkholderia vaccines: are we moving forward? Front Cell Infect Microbiol. 2013;3:5.
   PubMed Web of Science ®Google Scholar
• Peacock SJ, Limmathurotsakul D, Lubell Y, et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis. 2012;6(1):e1488.
   PubMed Web of Science ®Google Scholar
• Patel N, Conejero L, De Reynal M, et al. Development of vaccines against burkholderia pseudomallei. Front Microbiol. 2011;2:198.
   PubMed Web of Science ®Google Scholar
• West TE, Frevert CW, Liggitt HD, et al. Inhalation of Burkholderia thailandensis results in lethal necrotizing pneumonia in mice: a surrogate model for pneumonic melioidosis. Trans R Soc Trop Med Hyg. 2008;102(Suppl 1):S119–126.
   PubMedGoogle Scholar
• Glass MB, Gee JE, Steigerwalt AG, et al. Pneumonia and septicemia caused by Burkholderia thailandensis in the United States. J Clin Microbiol. 2006;44(12):4601–4604.
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Sayapina LV, Corbel MJ, et al. Russian vaccines against especially dangerous bacterial pathogens. Emerg Microbes Infect. 2014;3(12):e86.
   PubMed Web of Science ®Google Scholar
• Burtnick MN, Heiss C, Roberts RA, et al. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol. 2012;2:108.
   PubMed Web of Science ®Google Scholar
• Petersen H, Nieves W, Russell-Lodrigue K, et al. Evaluation of a Outer Membrane Vesicle Vaccine in Nonhuman Primates. Procedia Vaccinol. 2014;8:38–42.
   PubMedGoogle Scholar
• Whitlock GC, Robida MD, Judy BM, et al. Protective antigens against glanders identified by expression library immunization. Front Microbiol. 2011;2:227.
   PubMed Web of Science ®Google Scholar
• Jenjaroen K, Chumseng S, Sumonwiriya M, et al. T-cell responses are associated with survival in acute melioidosis patients. PLoS Negl Trop Dis. 2015;9(10):e0004152.
   PubMed Web of Science ®Google Scholar
• Bondi SK, Goldberg JB. Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev Vaccines. 2008;7(9):1357–1365.
   PubMed Web of Science ®Google Scholar